Small Animal Clinical Sciences, Gastrointestinal Laboratory, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, Texas, United States of America.
Center for Companion Animal Studies, Colorado State University, Fort Collins, Colorado, United States of America.
PLoS One. 2020 Feb 6;15(2):e0228145. doi: 10.1371/journal.pone.0228145. eCollection 2020.
The gastrointestinal microbiome plays an important role in host health and there is increasing concern regarding the deleterious effects of pharmaceuticals on the fecal microbiome. The effect of anthelmintic therapy on the fecal microbiome in dogs has not yet been evaluated. The purpose of this study was to evaluate the effect of anthelmintic administration on the fecal microbiome of dogs with and without subclinical Giardia species and Cryptosporidium canis infections.
METHODOLOGY/PRINCIPAL FINDINGS: Part 1: 6 healthy adult research beagles with subclinical giardiasis and cryptosporidiosis were administered a commercially available preparation of febantel combined with pyrantel and praziquantel (FPP) orally daily for three days. Part 2: 19 healthy staff-owned dogs without giardiasis or cryptosporidiosis were divided into a treatment group (n = 9) that was administered fenbendazole orally daily for five days and an untreated control group (n = 10). For both parts of the study, feces were collected at multiple time points before and after anthelmintic (FPP or fenbendazole) administration. Fecal DNA was extracted for Illumina sequencing of the bacterial 16S rRNA gene and qPCR assays. Neither FPP nor fenbendazole treatment caused a significant change in alpha or beta diversity or the relative abundance of bacterial species. Upon univariate statistical analysis neither FPP or fenbendazole caused minimal changes in the fecal microbiota.
FPP administration was associated with minimal alterations of the fecal microbiome of healthy research beagles with subclinical giardiasis and cryptosporidiosis. Fenbendazole administration was associated with minimal alterations of the fecal microbiome of healthy staff owned dogs.
胃肠道微生物群在宿主健康中起着重要作用，人们越来越关注药物对粪便微生物群的有害影响。驱虫治疗对狗粪便微生物群的影响尚未得到评估。本研究的目的是评估驱虫治疗对有和没有隐孢子虫和贾第鞭毛虫感染的无症状犬粪便微生物群的影响。
方法/主要发现：第 1 部分：6 只健康成年研究比格犬患有隐孢子虫和贾第鞭毛虫病，每日口服市售的芬苯达唑联合吡喹酮和噻嘧啶（FPP），连续 3 天。第 2 部分：19 只无隐孢子虫或贾第鞭毛虫病的员工所有犬分为治疗组（n = 9），每日口服芬苯达唑连续 5 天，未治疗对照组（n = 10）。在研究的两部分中，在驱虫（FPP 或芬苯达唑）前和后多次采集粪便。提取粪便 DNA，进行 Illumina 测序细菌 16S rRNA 基因和 qPCR 检测。FPP 或芬苯达唑治疗均未导致 alpha 或 beta 多样性或细菌物种相对丰度发生显著变化。在单变量统计分析中，FPP 或芬苯达唑均未导致粪便微生物群发生最小变化。
FPP 给药与患有隐孢子虫和贾第鞭毛虫病的无症状研究比格犬的粪便微生物群的最小变化相关。芬苯达唑给药与健康员工拥有的狗的粪便微生物群的最小变化相关。
